MAZE Maze Therapeutics, Inc.
Price Chart
Executive Summary
Three Maze Therapeutics insiders sold a combined $1.20M in open-market stock over a 6-day window, including the CEO, President/R&D/CMO, and CSBO. None of these sales are 10b5-1 plan trades — all are fully discretionary. The CEO sold the largest tranche ($666K) right before a 2% stock dip, and the President sold after an additional 1.8% decline. At a $1.3B market cap, the cluster represents 0.09% of shares outstanding, falling below the 0.1% materiality threshold, but the complete lack of any insider buying and the uniform selling by the three most senior R&D/C-suite executives warrants heightened scrutiny ahead of the next catalyst event.
Key Financial Metrics
Actionable Insight
While the absolute dollar amount is routine for a $1.3B market cap, the unanimous selling by the top three insiders (CEO, CSBO, President/CMO) without a single open-market buy creates a bearish optical signal. The CROSS-FILING ACTUARIAL AMPLIFIER applies (cluster-insider-trades + multiple context categories), suggesting these trades may be signaling ahead of earnings or a corporate event. Monitor for any 8-K (2.02 earnings miss or 2.05 restructuring) in the next 14 days — a negative event would validate the cluster's timing and could trigger a 5-7% downside move given the stock's poor T+20 historical calibration.
Key Facts
- CEO Jason Coloma sold 25,600 shares at $26.02 on May 26 for $666K
- CSBO Atul Dandekar sold 7,500 shares at $26.34 on May 29 for $198K
- President/CMO Harold Bernstein sold 13,253 shares at $25.57 on June 1 for $339K
- Bernstein and Dandekar each exercised stock options at $10.42 to facilitate their sales
- Total insider selling in the cluster: $1.20M, representing ~0.09% of market cap
- No open-market insider purchases by any executive in the trailing 30-day period
- 5 total insider sells in the past 30 days totaling $1.4M (includes this cluster)
- Historical model performance on MAZE shows 0% win rate at T+20 with -16.73% average return on settled calls
Financial Impact
Insider selling of $1.2M, or ~0.09% of $1.3B market cap — below the 0.1% materiality threshold
Risk Factors
- Uniform insider selling without any buys increases the risk of adverse news flow near-term
- Historical MAZE calls underperformed SPY by -19.6% at T+20, indicating persistent selling pressure or disappointing catalysts
- Cross-filing calibrations flag amplifiers but the score-4/5 neutral calls in the past have still produced -9% T+5 moves
- If the CEO's sale was pre-planned (10b5-1 is not disclosed in this data), that would reduce the bearish signal
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-MAZE-1780520527450 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $23.65 awaiting T+1 | awaiting T+1 | — | $24.05 (+1.69%) |
|
Jun 3, 2026
9d ago
|
Insider Cluster
| $25.40 $24.27 | ▲ +4.45% | ▲ +1.85% | $24.05 (+5.31%) |
|
May 22, 2026
21d ago
|
8-K
| $26.35 $26.05 | ▼ −1.14% | ▼ −1.15% | $24.05 (−8.73%) |
|
May 18, 2026
25d ago
|
Insider Cluster
| $24.46 $25.03 | ▲ +2.33% | ▲ +1.29% | $24.05 (−1.68%) |
|
May 12, 2026
4w ago
|
8-K
| $26.96 $26.96 | · 0.00% | ▲ +0.00% | $24.05 (−10.79%) |
|
May 12, 2026
4w ago
|
Press Release
| $26.96 $26.96 | · 0.00% | ▲ +0.00% | $24.05 (−10.79%) |
|
Apr 22, 2026
7w ago
|
424B5
| $26.01 $25.81 | ▼ −0.77% | ▼ −1.55% | $24.05 (−7.54%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $31.73 $31.71 | ▼ −0.06% | ▲ +1.71% | $24.05 (−24.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access